search
Back to results

Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

Primary Purpose

Peripheral Vascular Disease

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
GRST Peripheral Catheter System
Sponsored by
Vessix Vascular, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Vascular Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is ≥18 years of age
  • Patient is Rutherford category 2-4
  • De novo lesion in the SFA or popliteal artery with a diameter stenosis ≥50%
  • Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%
  • Target lesion stenosis has a length of ≤100 mm based on visual assessment
  • Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment
  • Angiographic evidence of distal runoff defined as minimum one (1) patent tibial artery with a straight flow to the foot
  • Patient is willing and able to provide written informed consent prior to any study specific procedure
  • Patient is willing and able to comply with specified follow-up evaluations at the specified times

Exclusion Criteria:

  • Any prior intervention in the intended target lesion including 10 mm proximal or distal from the intended treatment area
  • Evidence of thrombus in the target vessel
  • Prior ipsilateral or contralateral lower limb arterial bypass
  • Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure
  • Target lesion is severely calcified
  • Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
  • Any planned surgery within 30 days of the study procedure.
  • Renal failure (serum creatinine > 2.0 mg/dL)
  • Female with childbearing potential without a negative pregnancy test
  • Patient has had an organ transplant
  • Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study
  • In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    1

    Arm Description

    GRST Peripheral Catheter System

    Outcomes

    Primary Outcome Measures

    Major adverse clinical events rate

    Secondary Outcome Measures

    Binary restenosis
    Target lesion revascularization
    Amputation rate
    Technical success
    Serious adverse events rate, including major adverse clinical events

    Full Information

    First Posted
    September 9, 2008
    Last Updated
    August 12, 2013
    Sponsor
    Vessix Vascular, Inc
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00751283
    Brief Title
    Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities
    Official Title
    Minnow Medical GRST Peripheral Catheter System First-in-Man Study Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2013
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Data was inconclusive
    Study Start Date
    August 2007 (undefined)
    Primary Completion Date
    November 2010 (Actual)
    Study Completion Date
    May 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Vessix Vascular, Inc

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the safety and efficacy of the Minnow Medical GRST Peripheral Catheter System in the treatment of new lesions in the superficial femoral artery or the popliteal artery.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Peripheral Vascular Disease

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    GRST Peripheral Catheter System
    Intervention Type
    Device
    Intervention Name(s)
    GRST Peripheral Catheter System
    Intervention Description
    Treatment to dilate stenoses and reduce plaque in treated vessels
    Primary Outcome Measure Information:
    Title
    Major adverse clinical events rate
    Time Frame
    Up to 30 days
    Secondary Outcome Measure Information:
    Title
    Binary restenosis
    Time Frame
    30 days, 3 months, 6 months
    Title
    Target lesion revascularization
    Time Frame
    30 days, 3 months, 6 months
    Title
    Amputation rate
    Time Frame
    30 days, 3 months, 6 months
    Title
    Technical success
    Time Frame
    Treatment
    Title
    Serious adverse events rate, including major adverse clinical events
    Time Frame
    30 days, 3 months, 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient is ≥18 years of age Patient is Rutherford category 2-4 De novo lesion in the SFA or popliteal artery with a diameter stenosis ≥50% Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99% Target lesion stenosis has a length of ≤100 mm based on visual assessment Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment Angiographic evidence of distal runoff defined as minimum one (1) patent tibial artery with a straight flow to the foot Patient is willing and able to provide written informed consent prior to any study specific procedure Patient is willing and able to comply with specified follow-up evaluations at the specified times Exclusion Criteria: Any prior intervention in the intended target lesion including 10 mm proximal or distal from the intended treatment area Evidence of thrombus in the target vessel Prior ipsilateral or contralateral lower limb arterial bypass Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure Target lesion is severely calcified Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated). Any planned surgery within 30 days of the study procedure. Renal failure (serum creatinine > 2.0 mg/dL) Female with childbearing potential without a negative pregnancy test Patient has had an organ transplant Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Dierk Scheinert, MD
    Organizational Affiliation
    Universität Leipzig Herzzentrum
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

    We'll reach out to this number within 24 hrs